ERBB2 and non-small cell lung carcinoma: Because neither TKIs nor ADCs have been approved as first‐line treatments for HER2‐mutated NSCLC patients with advanced disease [18], immune checkpoint inhibitors (ICIs) with/without platinum doublet chemotherapy serve as the standard first‐line therapy [19].